Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103835 | 0.85 | LMNA (0.56) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL541337 | 0.79 | MEN1 (0.68) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL542596 | 0.78 | MEN1 (0.63) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL1093175 | 0.78 | MEN1 (0.49) | MEN1KMT2ALMNAMMP2MMP13 | |
| SCHEMBL539101 | 0.77 | LMNA (0.74) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL542606 | 0.77 | MEN1 (0.64) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL542399 | 0.77 | MEN1 (0.64) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL542522 | 0.73 | MEN1 (0.49) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL543049 | 0.73 | MEN1 (0.52) | MEN1KMT2ALMNAADAM17MMP2 | |
| SCHEMBL122883 | 0.72 | ACACB (0.45) | KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | MEN1 3926/4885KMT2A 1414/4885LMNA 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.